Individual participant meta-analysis of 2 RCTs (6,734 patients with ACS undergoing PCI): CYP2C19 genotype-guided P2Y12 therapy did not change 12-month bleeding or MACE vs conventional therapy; guided de-escalation reduced bleeding (HR 0.77).
Meta-analysisn = 6,734
Galli et al. Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome: A Combined Analysis of TAILOR-PCI and POPular Genetics